Development of a novel immunoassay for the assessment of plasma Gas6 concentrations and their variation with hormonal status

Clinical Chemistry

Volumn 53, Issue 10, 2007, Pages 1808-1813

  Clauser, Sylvain ^a,b,c   Peyrard, Séverine ^a   Gaussem, Pascale ^a,c   Crespin, Malvina ^c   Emmerich, Joseph ^c   Aiach, Martine ^a,c   Borgel, Delphine ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; GROWTH ARREST SPECIFIC PROTEIN 6; ORAL CONTRACEPTIVE AGENT; VITAMIN K GROUP;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOASSAY; MALE; MENSTRUAL CYCLE; NORMAL HUMAN; ORAL CONTRACEPTION; PROTEIN FUNCTION; SEX DIFFERENCE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHINYL ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEVONORGESTREL; MALE; PLASMA; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 34848875122     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.089102     Document Type: Article

References (25)

1. Evenas P, Garcia de Frutos P, Nicolaes GA, Dahlback B. The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa. Thromb Haemost 2000;84:271-7.
2. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996;271:30022-7.
3. Goruppi S, Ruaro E, Schneider C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 1996;12:471-80.
4. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001;7:215-21.
5. Balogh I, Hafizi S, Stenhoff J, Hansson K, Dahlback B. Analysis of Gas6 in human platelets and plasma. Arterioscler Thromb Vasc Biol 2005;25:1280-6.
6. Clauser S, Bachelot-Lozat C, Fontana P, Gaussem P, Remones V, Aiach M, et al. Physiological plasma Gas6 levels do not influence platelet aggregation. Arterioscler Thromb Vasc Biol 2006;26:e22.
7. Burnier L, Borgel D, Angelillo-Scherrer A, Fontana P. Plasma levels of the growth arrest-specific gene 6 product (Gas6) and antiplatelet drug responsiveness in healthy subjects. J Thromb Haemost 2006;4:2283-4.
8. Munoz X, Sumoy L, Ramirez-Lorca R, Villar J, de Frutos PG, Sala N. Human vitamin K-dependent GAS6: gene structure, allelic variation, and association with stroke. Hum Mutat 2004;23:506-12.
9. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001;103:163-82.
10. Mo R, Tony Zhu Y, Zhang Z, Rao SM, Zhu YJ. GAS6 is an estrogen-inducible gene in mammary epithelial cells. Biochem Biophys Res Commun 2007;353:189-94.
11. Saposnik B, Borgel D, Aiach M, Gandrille S. Functional properties of the sex-hormone-binding globulin (SHBG)-like domain of the anticoagulant protein S. Eur J Biochem 2003;270:545-55.
12. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-95.
13. Sere KM, Janssen MP, Willems GM, Tans G, Rosing J, Hackeng TM. Purified protein S contains multimeric forms with increased APC-independent anticoagulant activity. Biochemistry 2001;40:8852-60.
14. Taupin JL, Gualde N, Moreau JF. A monoclonal antibody based ELISA for quantitation of human leukaemia inhibitory factor. Cytokine 1997;9:112-8.
15. Boehme MW, Stremmel W. Comparison of three commercially available thrombomodulin ELISA kits. J Immunol Methods 2004;286:231-40.
16. Declerck PJ, Moreau H, Jespersen J, Gram J, Kluft C. Multicenter evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 1993;70:858-63.
17. Dempfle CE, Zips S, Ergul H, Heene DL. The Fibrin Assay Comparison Trial (FACT): evaluation of 23 quantitative D-dimer assays as basis for the development of D-dimer calibrators. FACT study group. Thromb Haemost 2001;85:671-8.
18. Gibot S, Massin F, Cravoisy A, Dupays R, Barraud D, Nace L, et al. Growth arrest-specific protein 6 plasma concentrations during septic shock. Crit Care 2007;11:R8.
19. Darney PD. The androgenicity of progestins. Am J Med 1995;98:104S-10S.
20. Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001;63:1-11.
21. Lu Q, Gore M, Zhang Q, Camenisch T, Boast S, Casagranda F, et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 1999;398:723-8.
22. D'Arcangelo D, Gaetano C, Capogrossi MC. Acidification prevents endothelial cell apoptosis by Axl activation. Circ Res 2002;91:e4-12.
23. Nakano T, Kawamoto K, Higashino K, Arita H. Prevention of growth arrest-induced cell death of vascular smooth muscle cells by a product of growth arrest-specific gene, gas6. FEBS Lett 1996;387:78-80.
24. Boddaert J, Mallat Z, Fornes P, Esposito B, Lecomte D, Verny M, et al. Age and gender effects on apoptosis in the human coronary arterial wall. Mech Ageing Dev 2005;126:678-84.
25. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-90.